Introduction {#Sec1}
============

Intravenous busulfan (ivBu) has been used as a conditioning regimen for hematopoietic stem cell transplantation \[[@CR1]--[@CR3]\]. Busulfan is known to cause seizures; at high doses it passes freely through the blood--brain barrier, resulting in high concentrations in the central nervous system, thus increasing the risk of convulsive seizures. Busulfan-induced seizures are generally tonic-clonic in nature. It has been reported that the incidence of seizures is 10% (range 1.8--40%) when high-dose busulfan is used without preventive measures \[[@CR4]\]. Drugs used to prevent busulfan-induced seizures must be fast acting, should not increase the toxicity of the conditioning agents, and should not alter the pharmacokinetics of the conditioning regimen \[[@CR4], [@CR5]\]. While the package insert for busulfan recommends anticonvulsant prophylaxis, no information regarding a specific drug or its administration is provided. There are many reports describing the use of antiepileptic drugs, such as phenytoin and valproic acid, as well as benzodiazepines, such as clonazepam or lorazepam, as prophylactic treatments against busulfan-induced seizures \[[@CR4], [@CR6], [@CR7]\]. While there are many reported cases of phenytoin use, it reportedly induces drug metabolizing enzymes, thereby interacting with the metabolism of cyclophosphamide, a drug used in the conditioning regimen \[[@CR8], [@CR9]\]. More recently, there have been reports of the use of levetiracetam as a prophylaxis against busulfan-induced seizures in pediatrics; however, there is little information regarding its use in adults \[[@CR5], [@CR10], [@CR11]\]. The pharmacokinetic features of levetiracetam, including approximately 100% bioavailability and linear pharmacokinetics, enable its usage without therapeutic drug monitoring (TDM) \[[@CR12], [@CR13]\]. Additionally, the drug has no effect on cytochrome P450 metabolic enzymes \[[@CR14]\]. In this study, we conducted a retrospective analysis of prophylactic anticonvulsant agents, as well as their adverse effects, when used in cases of ivBu administration at our institution.

Materials and methods {#Sec2}
=====================

We included 104 cases of ivBu usage during hematopoietic stem cell transplantation at the Shizuoka Cancer Center from May 1, 2010 to April 30, 2017 in this study. The main study endpoints were seizure and involuntary movement prevention rates during ivBu administration. In addition, the presence of nausea, vomiting, and oral mucositis was assessed from the start of the conditioning regimen to the day of transplantation. Oral mucositis, total bilirubin, and veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) were assessed from the start of the conditioning regimen to 28 days post-transplantation as secondary endpoints to confirm that ivBu-induced adverse events were not enhanced by the use of anticonvulsants. Moreover, neutrophil engraftment was assessed. Neutrophil engraftment was defined as the first day of an absolute neutrophil count \> 500/µL on three consecutive measurements. The Common Terminology Criteria for Adverse Events (version 4.0) and the Modified Seattle Criteria were used for retrospective assessment of the medical records \[[@CR15], [@CR16]\].

For this type of study formal consent is not required.

Statistical analysis {#Sec3}
--------------------

We used Fisher's exact test, and *p* values \< 0.05 were considered statistically significant. All statistical analyses were performed with EZR version 3.2.2; EZR is a modified version of "R Commander" that includes statistical functions frequently used in biostatistics.

Results {#Sec4}
=======

The patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. A diagnosis of "other" included anaplastic large cell lymphoma, mixed phenotype acute leukemia B/myeloid, Hodgkin's lymphoma/nodular sclerosis, myelofibrosis, and adult T-cell leukemia/lymphoma, representative of one individual each. The ivBu2 + α conditioning regimen included the use of intravenous busulfan at 6.4 mg/kg in combination with another drug. For the ivBu4 + β conditioning regimen, ivBu was administered at 12.8 mg/kg in combination with another drug.

Table 1Patient characteristics as *N* (%) or median (range)PHTLEV*N*7034Male sex46 (65.7)18 (52.9)Age (years)58 (17--74)58 (35--69)Diagnosis AML40 (57.1)10 (29.4) MDS24 (34.3)11 (32.4) CML4 (5.7)3 (8.8) PCNSL05 (14.7) DLBCL2 (2.9)0 Other05 (14.7)Donor/stem cell source Autologous peripheral blood05 (14.7) Related peripheral blood14 (20.0)4 (11.8) Unrelated peripheral blood05 (14.7) Unrelated bone marrow42 (60.0)10 (29.4) Unrelated cord blood14 (20.0)10 (29.4)Conditioning regimen ivBu/CY20 (28.6)9 (26.5) FB48 (11.4)0 ATG/FB4 ± AraC37 (52.9)18 (52.9) FB4/TBI ± AraC2 (2.9)4 (11.8) ivBu2 + α3 (4.3)0 ivBu4 + β03 (8.8)Emesis prophylaxis Granisetron70 (100)10 (29.4) Palonosetron01 (2.9) Palonosetron + fosaprepitant023 (67.6)*AML* acute myeloid leukemia,*MDS* myelodysplastic syndrome,*CML* chronic myeloid leukemia, *PCNSL* primary central nervous system lymphoma,*DLBCL* diffuse large B cell lymphoma,*ivBu/CY* intravenous busulfan at 12.8 mg/kg + cyclophosphamide,*ivBu2 + α* intravenous busulfan at 6.4 mg/kg + other drugs,*FB4* fludarabine + intravenous busulfan at 12.8 mg/kg,*ATG* anti-thymocyte globulin (rabbit),*AraC* cytarabine,*TBI* total body irradiation,*ivBu4 + β* intravenous busulfan at 12.8 mg/kg + other drugs,*PHT* phenytoin,*LEV* levetiracetam.

Phenytoin and levetiracetam were used as anticonvulsants in 70 (67.3%) and 34 (32.7%) cases, respectively. All cases of prophylaxis using phenytoin were administered intravenously. One case of prophylaxis using phenytoin was started on the initial day of ivBu administration, while all other cases were started the day before ivBu administration. The dose of phenytoin before ivBu administration was 125 mg/day in one case, 150 mg/day in two cases, and 300 mg/day in the remaining cases. After initiation of ivBu administration, the dose of phenytoin was 250 mg/day in two cases and 300 mg/day in the remaining cases. All cases of prophylaxis using oral levetiracetam were given 1000 mg/day and began 2 days prior to the start of ivBu administration. Phenytoin or levetiracetam was administered as a prophylactic treatment until the day after the termination of ivBu administration.

Under phenytoin anticonvulsant prophylaxis, the seizure and involuntary movement prevention rates were 98.6 and 87.1%, respectively. Prevention rates associated with levetiracetam were 100 and 97.1% for seizures and involuntary movements, respectively. There was one confirmed case of a seizure from a patient having received 125 mg/day phenytoin 1 day before ivBu administration; the seizure was identified on the second day of ivBu administration, at which point the conditioning regimen was changed by the attending physician in consideration of the difficulties associated with continuing the existing regimen.

Assessments of the incidence of nausea, vomiting, and oral mucositis are shown in Table [2](#Tab2){ref-type="table"}. Grade one (Gr1) oral mucositis was found in 55.7% and Gr2 oral mucositis was found in 2.9% of patients receiving phenytoin prophylaxis, from the start of the conditioning regimen to transplantation day; in contrast, Gr1 oral mucositis was found in 38.2% and Gr2 oral mucositis was found in 0% of patients receiving levetiracetam prophylaxis (*p* = 0.12). Gr3 oral mucositis was not observed in either prophylactic treatment group. However, the incidences of oral mucositis in the phenytoin prophylaxis groups were Gr1: 31.4%, Gr2: 25.7%, and Gr3: ≤ 35.7% from the start of the conditioning period to 28 days post-transplantation; incidences of oral mucositis were Gr1: 14.7%, Gr2: 44.1%, and Gr3: ≤ 35.3% (*p* = 0.18) in the levetiracetam prophylaxis group. There were no significant differences in the occurrence of adverse events, including nausea, vomiting, oral mucositis, and liver dysfunction based on differences in anticonvulsant usage.

Table 2Incidence of nausea, vomiting, oral mucositis, and liver toxicity, *N* (%)PHT (*n* = 70)LEV (*n* = 34)*p* valueNausea All grades50 (71.4)30 (88.2)0.08 Grade 3 ≤12 (17.1)1 (2.9)0.06Vomiting All grades34 (48.6)18 (52.9)0.84 Grade 3 ≤3 (4.3)00.55Mucositis oral Until transplant day  All grades41 (58.6)13 (38.2)0.06  Grade 3 ≤00 Until day 28  All grades65 (92.9)32 (94.1)1  Grade 3 ≤25 (35.7)12 (35.3)1T-Bil All grades29 (41.4)10 (29.4)0.28 Grade 3 ≤2 (2.9)01VOD/SOS2 (2.9)01*PHT* phenytoin, *LEV* levetiracetam, *T-Bil* total bilirubin, *VOD/SOS* veno-occlusive disease/sinusoidal obstruction syndrome

The median number of days to neutrophil engraftment was 15.5 (range 11--24) days and 15.0 (10--31) days in phenytoin and levetiracetam groups, respectively.

Discussion {#Sec5}
==========

We conducted a retrospective study to assess the types of anticonvulsant drugs and their prophylactic effects when used in cases of ivBu administration. Previous studies have reported that seizures occur at a frequency of 1--40% in cases of busulfan administration with no prophylactic anticonvulsant use \[[@CR4], [@CR17]\]. In our study, seizure prevention rates of 98.6 and 100% were observed when phenytoin and levetiracetam were used as prophylactic treatments against ivBu-induced seizures, respectively. There were no statistically significant differences between anticonvulsant types. However, a confirmed seizure case was observed with phenytoin prophylaxis, resulting in difficulty with the use of ivBu and a subsequent change in conditioning agent. Previous reports have identified a 1% frequency in the incidence of seizures even under prophylactic anticonvulsant administration \[[@CR18], [@CR19]\]. ivBu-induced seizures may occur even in the presence of anticonvulsant agents, resulting in a sudden change in the conditioning schedule. Therefore, there is a need for additional prophylactic anticonvulsants to prevent ivBu-induced seizures and avoid sudden changes in the conditioning schedule.

To be used as a prophylactic agent, a drug should not enhance the toxicity associated with the conditioning regimen \[[@CR4]\]. No statistically significant differences in nausea and vomiting were observed between the anticonvulsants studied, during the conditioning regimen. The incidence of vomiting in the levetiracetam prophylaxis group was less than that of previous reports \[[@CR1], [@CR20]\]. The combination of palonosetron + fosaprepitant was used for its antiemetic effect in 67.6% of patients in the levetiracetam prophylaxis group. Palonosetron is a second-generation 5-hydroxytryptamine 3 receptor antagonist that is more effective in the suppression of delayed nausea and vomiting than the first-generation 5-hydroxytryptamine 3 receptor antagonist, granisetron \[[@CR21]\]. In addition, nausea and vomiting are alleviated by a combination of 5-hydroxytryptamine 3 receptor antagonists and the neurokinin-1 receptor antagonist, fosaprepitant; fosaprepitant is the pro-drug of aprepitant \[[@CR22], [@CR23]\]. The ability to use both substances in recent years has resulted in improvements in the control of vomiting over that observed in past reports. This is in contrast to oral mucositis, with no noted differences in its high incidence rate. Moreover, the presentation of VOD/SOS did not differ significantly from previous reports \[[@CR6], [@CR10], [@CR20], [@CR24]\]. Furthermore, the median number of days to neutrophil engraftment did not differ significantly in a previous systematic review \[[@CR25]\], and it may be assumed that anticonvulsant administration had no significant effects on adverse events associated with ivBu administration.

This study assessed the use of phenytoin or levetiracetam as anticonvulsant agents. TDM is sometimes required with phenytoin, as it displays non-linear pharmacokinetics. In contrast, levetiracetam is approximately 100% bioavailable, with no effects on cytochrome P450 metabolic enzymes. Consequently, levetiracetam can be used orally or intravenously without consideration of the cytochrome P450 enzyme system or TDM \[[@CR12]--[@CR14]\]. While slight involuntary movements were observed, there was an absence of seizures in the levetiracetam prophylaxis group. An oral mucositis score of Gr2 or less was observed from the start of conditioning to transplantation, enabling drugs to be administered orally throughout the ivBu administration period. Oral levetiracetam can be administered continually as a prophylactic agent against ivBu-induced seizures; therefore, medical personnel may consider oral levetiracetam administration to be a more convenient method than that required for phenytoin.

Limitations exist in the current study. First, this was a retrospective study carried out in a single institution with a limit to the drugs that could be used as anticonvulsants. The second was the inability to conduct pharmacokinetic monitoring of ivBu. As such, we were unable to evaluate the effects of phenytoin and levetiracetam on ivBu pharmacodynamics. The third limitation concerns difficulties in adjusting the dose of phenytoin, attributable to the short administration period, with a consequent inability to conduct TDM for phenytoin. Therefore, it is unclear whether optimal blood concentrations of phenytoin were maintained during ivBu administration. Fourth, direct hematological toxicity induced by levetiracetam could not be evaluated owing to strong myelosuppression of myeloablative conditioning \[[@CR26], [@CR27]\].

In conclusion, prophylactic anticonvulsant administration is necessary to facilitate transplantations without sudden changes in conditioning schedules. Further, our results show that levetiracetam can be used to effectively prevent busulfan-induced seizures in adults. Moreover, the use of levetiracetam is convenient for medical staff, as it can be administered orally and TDM is not required. Importantly, the absence of adverse events induced with oral administration of levetiracetam during ivBu administration is indicative of its application for continued administration and its convenience of use by medical staff. These results support clinical decision making by providing evidence for the use of levetiracetam during ivBu conditioning. In the future, it is necessary to consider prospective studies to validate supportive care for better busulfan-induced seizure prevention.
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